![]() | |
Names | |
---|---|
Preferred IUPAC name
4-(2,2-Dimethylpropanamido)butanoic acid | |
Identifiers | |
3D model (JSmol) |
|
ChemSpider |
|
ECHA InfoCard | 100.067.287 ![]() |
EC Number |
|
KEGG |
|
MeSH | N-trimethylacetyl-4-aminobutyric+acid |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C9H17NO3 | |
Molar mass | 187.239 g·mol−1 |
Pharmacology | |
N06AX15 (WHO) | |
Oral | |
Pharmacokinetics: | |
6.4 hours | |
Legal status |
|
Related compounds | |
Related alkanoic acids |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Pivagabine (INN; brand name Tonerg), also known as N-pivaloyl-γ-aminobutyric acidorN-pivaloyl-GABA, is an antidepressant and anxiolytic drug which was introduced in Italy in 1997 for the treatment of depressive and maladaptive syndromes. But it was discontinued in Italy (according to Martindale). Originally believed to function as a prodrugtoGABA,[1] pivagabine is now believed to act somehow via modulation of corticotropin-releasing factor (CRF).[2][3][4][5][6]
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|